Why Hims & Hers Stock Dropped Today

Hims & Hers Health (NYSE: HIMS) tumbled 5.6% through 12:20 p.m. ET Thursday after Bank of America analysts gave mixed messages on the stock this morning.

Raising its price target on the shares to $21, reports The Fly, BofA nonetheless reiterated an "underperform" (i.e., sell) rating on Hims & Hers stock. Investors are taking the hint, and doing just that.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »

Why BofA worries about Hims & Hers

Hims & Hers stock has been a mega-outperformer for investors, growing more than 600% over the past year, largely on the back of its compounded semaglutide products that mimic the effect of Ozempic and similar weight loss drugs from Big Pharma companies like Novo Nordisk and Eli Lilly. But Hims & Hers' opportunity, which emerged as Novo and Lilly were unable to satisfy demand for GLP-1 products, has also created a risk for the stock, reports BofA.

On the one hand, the banker sees "upside" to Hims & Hers' Q4 revenue estimates. BofA furthermore predicts that Q1 2025 guidance will be "meaningfully" ahead of analyst expectations -- that Hims & Hers will guide to an earnings beat.

The problem is how Hims & Hers makes that happen.

BofA estimates that by Q2 2025, GLP-1 sales could comprise more than 50% of Hims & Hers' sales, overweighting the company's reliance on just one product for half its business. Since it's only a matter of time before Novo and Lilly have scaled up enough that there will be no need for compounders like Hims & Hers to make up the deficit of GLP-1 supply and that business disappears, BofA predicts sales could soon fall off a cliff.

Is Hims & Hers stock a sell?

But here's the curious thing: Most Wall Street analysts see Hims & Hers revenue continuing to grow going forward, and indeed roughly doubling in size by 2027. Still, even optimists only forecast $0.86 in earnings that year, which values the stock at more than 77 times earnings three years away.

That's quite a high price to pay. I agree with BofA that it makes Hims & Hers stock a sell.

Don’t miss this second chance at a potentially lucrative opportunity

Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.

On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:

• Nvidia: if you invested $1,000 when we doubled down in 2009, you’d have $361,026!*
• Apple: if you invested $1,000 when we doubled down in 2008, you’d have $46,425!*
• Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $562,659!*

Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.

Learn more »

*Stock Advisor returns as of February 3, 2025

Bank of America is an advertising partner of Motley Fool Money. Rich Smith has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bank of America. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.